Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL

Clinical trial NCT07058103 · RECRUITING

Trial details

NCT number: NCT07058103
Sponsor: The Affiliated Hospital of Xuzhou Medical University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Angioimmunoblastic T-Cell Lymphoma Recurrent Angioimmunoblastic T-Cell Lymphoma Refractory

Start date: 2025-04-01
Primary completion: 2028-04-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.